|
|
|
|
|
Issue 37
|
5109 Kali Era, Sarvajit
Year, Chaitra/Vaisakha
month
2065
Vikramarka Era, Sarvajit
Year, Chaitra/Vaisakha
month
1929
Salivahana
Era, Sarvajit
Year, Chaitra/Vaisakha
month
2007 AD, April
|
|
Home
Management
AJIN
TSJ
MS
Vegetarian Links
Disclaimer
Soliciataion
Contact
VPC
More Links
Vedah
|
IP Hall of Fame
The IP Hall of Fame honours those who have made an outstanding contribution
to the development of intellectual property law and practice. Devised and
developed by leading IP publication Intellectual Asset Management magazine,
it identifies individuals who have helped to establish intellectual property
as one of the key business assets of the 21st century. The aim is not only
to acknowledge the vital role played by these innovators in fostering today's
vibrant IP environment and ensuring its continued health, but also to show
how central IP is to the global economy and to the wellbeing of people around
the world.
The first 23 inductees to the IP Hall of Fame included two US presidents,
a Japanese prime minister and one of France's greatest authors. Both Thomas
Jefferson and James Madison were honoured for their insistence that intellectual
property rights be specifically safeguarded by the US Constitution, while
Korekiyo Takahashi was recognised as the founding father of Japan's patent
system. Victor Hugo, meanwhile, was nominated as a prime mover behind the
creation of the Berne Convention on Copyright, which to this day helps safeguard
the rights of authors and other copyright owners in over 150 countries. Other
inductees included the great American inventor Thomas Edison and Sir Edward
Coke, a 17th century English courtier who played a pivotal role in the foundation
of modern patent rights.
Among the inductees from the present day were Microsoft's IP chief Marshall
Phelps and Bruce Lehman, a former Commissioner of the US Patent and Trademark
Office and Under-secretary of Commerce during the Clinton presidency. European
representatives include Klaus-Dieter Langfinger, head of IP at BASF and a
prime advocate for IP rights in Europe.
A full list of Academy members can be found here. http://www.iphalloffame.com/info/Members.aspx
Value of IP
Business Week magazine recently published that the Coca-Cola trademark has
been valued in $70,450 million dollars. However, an intangible asset wouldn't
be worth anything without proper protection. Nowadays, Intellectual Property
valuation is a reference point in order to take important business decisions.
Recently, a group of bipartisan legislators in both the Senate and House
of Representatives introduced patent reform bills - the Patent Reform Act
of 2007.
The bills can be found at:
Senate: http://www.patentlyo.com/patent/files/PatentReform2007.SENATE.pdf
House: http://www.patentlyo.com/patent/files/PatentReform2007.SENATE.pdf
Some highlights:
- First-to-file rights (35 U.S.C. § 102)
- Elimination of interference proceedings (35 U.S.C. §
135)
- Reform to make it easier to file a patent application without
the inventor's cooperation (35 U.S.C. § 115 and 118)
- Limitation of damages to only the economic value of the
improvement as compared to the prior-art (35 U.S.C. § 284)
- Specific limitations on when damages may be trebled for
willfulness art (35 U.S.C. § 284)
- Post-grant opposition proceedings and a reduction in the
litigation estoppel effect of reexaminations art (35 U.S.C. § 284 and
others)
The National Academy of Sciences Report on the patent system is a thoughtful
and balanced roadmap for reform. The NAS's four-pronged set of patent quality
and patent litigation reforms, based upon a comprehensive and inclusive four-year
study, can be found here: http://www.patentsmatter.com/issue/key_principles.php.
For more on Patent Reform visit:
http://www.patentlyo.com/patent/2007/04/patent_reform_a_1.html
http://271patent.blogspot.com/search/label/patent%20reform
http://www.patenthawk.com/blog/2007/04/patent_reform_principles_1.html#more
http://patentdocs.typepad.com/patent_docs/2007/04/they_just_dont_.html
http://www.mondaq.com/article.asp?articleid=47856&email_access=on
Patent
License Agreements: 10 Pitfalls
When drafting or negotiating a patent license agreement, a number of pitfalls
should be avoided or at least have their effects reduced. Failing that, the
rights and interests of the company, which you represent, might be affected,
if not altered. Whether you are the patent licensor or the patent licensee,
you will find hereinafter the 10 main points that should be borne in mind
so as to reduce or remove the major risks occurring upon drafting and negotiating
such patent license agreement. http://www.mondaq.com/article.asp?articleid=46966&email_access=on&login=true
Clean Renewable
Energy Bonds (CREBs)
The Internal Revenue Service (IRS) recently issued Notice 2007-26 (Notice)
soliciting applications from qualified issuers (including political subdivisions)
for allocations of volume cap to issue clean renewable energy bonds (CREBs)
for eligible clean renewable energy projects. Applications must be filed
with the IRS by July 13, 2007. CREBs are "tax-credit" bonds authorized in
an initial amount of $800 million by Congress in the Energy Incentives Act
of 2005. In 2006, Congress increased the authorized amount of CREBs from
$800 million to $1.2 billion and also extended the last date for the issuance
of CREBs to December 31, 2008. Before a qualified issuer can issue CREBs,
it must first obtain an allocation of volume cap from the IRS. Last year,
the IRS allocated the initial $800 million of volume cap to a total of 610
projects. For more visit: http://www.mondaq.com/article.asp?articleid=47312&email_access=on
AstraZeneca buys
MedImmune
AstraZeneca has been struggling recently to come up with new therapies, but
has been dealt a series of setbacks. The latest came when the drug giant
announced that it is abandoning an experimental heart drug. AstraZeneca has
abandoned its collaboration with AtheroGenics on its cardiac drug AGI-1067
after the drug failed to perform better than a placebo in a Phase III clinical
trial last month. AstraZeneca paid a $50 million licensing fee for development
rights to the therapy, which now revert back to AtheroGenics.
The pharma company needs some big late-stage products in the pipeline.
However, buying MedImmune won't bring much help on that score. AstraZeneca
paid more than a billion dollars recently for Cambridge Antibody, but the
MedImmune deal is the biggest buyout since the company was formed in 1999
by the merger of Astra and Zeneca. MedImmune, the Gaithersburg, MD-based
biotech company announced that it had agreed to sell out to AstraZeneca for
$15.6 billion in cash.
Zelnorm Withdrawal
Swiss pharmaceutical maker Novartis AG will stop selling a drug to relieve
constipation after it was linked to a higher chance of heart attack, stroke
and worsening heart chest pain that can become a heart attack, federal health
officials said. Novartis agreed to withdraw Zelnorm at the FDA's request,
the agency said in a public health advisory. Zelnorm, also called tegaserod
maleate, is a prescription medication approved for short-term treatment of
women with irritable bowel syndrome with constipation and for patients younger
than 65 with chronic constipation, the FDA said.
Herbal Medicine
in US and India
Last year, the U.S. Food and Drug Administration (FDA) has for the first
time approved a special extract of green tea as a prescription drug for the
topical (external) treatment of genital warts caused by the human papilloma
virus (HPV). The new drug, called Veregen (Polyphenon E) an ointment is the
first prescription botanical (herbal) drug approved by FDA under the "new"
drug amendments of 1962 that required drugs to be proved both safe and effective,
prior to marketing in the U.S. Given the thousands of years of history of
Ayurveda and natural medicine, you may assume that this drug is developed
by an Indian company. But no, MediGene, a German company developed
the above named herbal drug and it is marketed by Bradley Pharmaceuticals,
USA. http://bradpharm.com/. http://phx.corporate-ir.net/phoenix.zhtml?c=70567&p=irol-newsArticle_print&ID=974062&highlight=
The active drug ingredient, Polyphenon® E, represents a proprietary mixture
of phytochemicals produced from a partially purified water extract of green
tea leaves. Green tea, brewed from the leaves of the tea plant (Camellia
sinensis), is one of the most popular beverages worldwide. Unlike leaves
used for black or oolong teas, leaves used to prepare “green” tea do not
undergo a fermentation process. Therefore, green tea retains higher levels
of highly antioxidant polyphenolic compounds known as catechins. (http://www.fda.gov/cder/foi/label/2006/021902lbl.pdf)
Polyphenon E® Ointment is a product of global development. In 1997, Epitome
Pharmaceuticals Ltd., a privately owned Canadian company (Halifax, Nova Scotia)
licensed from Mitsui Norin, Ltd. (Tokyo, Japan), a patented method of treating
external genital warts through the topical application of Polyphenon®
E green tea extract, the patent for which extends through 2017. Epitome sublicensed
the technology to MediGene AG of Munich, Germany, which collaborated in two
multi-center Phase II clinical trials. In 2003 MediGene extended its license
to include the treatment of hyperplasia caused by papilloma viruses. In 2004
MediGene conducted two Phase III trials, one in Europe and another in the
Americas. Based on these trial results, MediGene submitted a New Drug Application
(NDA) to the FDA Center for Drug Evaluation and Research in September 2005.
FDA accepted the NDA for filing in early December 2005.
In India, there are about 17,000 species of higher plants and of which, 7500
are known for medicinal uses. This proportion is the highest for plants known
for their medical purposes in any other country of the world. After years
of apathy, the Pharmaceuticals Export Promotion Council, under the Ministry
of Commerce, along with Ayush (ayuerveda, yoga, unani, siddha and
homeopathy) is working on to standardize some herbal products and register
the product through a research panel. The Government is proposing to resource
map all medicinal plants available in the country.
Biotech in EU
The European Union has put together a set of recommendations aimed at fostering
the continent's biotech industry, which has traditionally lagged far behind
the U.S. in raising funds for emerging companies. The EU is looking for more
public-private partnerships to provide the cash needed for research, new
incentives for start-ups and more support for companies trying to manage
the continent's complex set of patent rules. An industry trade group, EuropaBio,
said that it has its doubts about the plan, largely because member countries
are being urged to take voluntary action. The EU and the U.S. each have about
2,000 biotech companies, but U.S. developers gained $3.1 billion in venture
funds in 2004 compared to $1.4 billion for European companies. The relative
lack of funding has hampered the growth of European drug developers, who
gained 34.8 percent of European drug patents to the Americans' 41.4 percent
share.
US BioVenture
in Indian Continent
The U.S. venture firm MPM Capital has created a partnership with India's
Reliance Life Sciences aimed at injecting fresh capital into the continent's
life sciences industry. RLS has become a partner in MPM BioVentures IV, a
$550 million fund, which will budget a portion of its investment dollars
for Indian biotech companies. The two firms are also considering the potential
of a new seed fund that would be devoted to Indian companies. The move is
a welcome development for India's biotech sector, which has been long on
potential and short on cash. It also offers another glimpse at the increasingly
global structure of drug development, as companies develop international
strategies for cutting costs and shortening development time frames.
Biotech Drugs
Biotech treatments, which are derived from naturally occurring proteins and
often given by injection, are expected to make up 26 percent of total prescription
spending in 2010, compared with about 20 percent in 2006. The increase is
due largely to higher prices and new uses for drugs originally approved for
rare conditions.
Generic companies, such as Mylan Laboratories Inc. and Teva Pharmaceuticals
Ltd., have long sought federal approval to market generic versions of biotech
drugs made by Amgen Inc. and Genentech Inc. among others. The competitive
stakes are high - for the companies and for consumers. Biotech drugs can
cost tens of thousands of dollars for a year's supply. Already, $12 billion
of the drugs sold each year no longer have patent protection, but under current
law, generic companies cannot sell similar versions. The Senate is expected
to vote soon on the one major pharmaceutical bill that is expected to pass
this year. The bill is nearly guaranteed to pass because it reauthorizes
the user fee program that helps fund the agency's drug review budget and
the odds are growing that the biotech generics issue won't be included. After
Democrats took control of Congress last year, generic firms renewed lobbying
for approval to produce biotechs, emphasizing the potential for reining in
escalating health care costs. But the biotech industry argues, as it has
for more than a decade, that the complexity of their products would make
it difficult for generic drug companies to safely copy them. Despite safety
concerns many experts, including a former FDA commissioner, think generic
biotech is inevitable for the United States, and point out that the European
Union already allows the practice. And consumer groups, such as AARP and
Families USA, have joined the Generic Pharmaceutical Association to lobby
for the law change. As momentum behind the issue has increased, the Biotechnology
Industry Organization trade group has suggested it is willing to compromise.
Generic Ambien
U.S. health officials have approved 13 cheaper generic alternatives to Ambien,
a blockbuster sleeping pill from France's Sanofi-Aventis, the Food and Drug
Administration said. The controversial drug, also known as zolpidem tartrate,
has been linked to potentially dangerous risks such as driving while asleep
and allergic reactions. Like Ambien and other popular sleep drugs, the new
generics will also have to carry warnings on their product labels, the FDA
said. Manufacturers cleared to make generic versions include Mylan Laboratories
Inc., Teva Pharmaceutical Industries Ltd., Roxane Laboratories Inc., Watson
Laboratories Inc., Ranbaxy Laboratories Ltd., Dr. Reddy's Laboratories Ltd.,
Apotex Inc. and Synthon Pharmaceuticals Inc. Genpharm Inc., Mutual Pharmaceutical
Company Inc., Caraco Pharmaceutical Laboratories Ltd., Carlsbad Technology
Inc. and Lek Pharmaceuticals also won FDA approval.
Genetic Wonder Drug
Made by PTC Therapeutics, a pill known as PTC124 has been staggeringly successful
in animal models. A study published today in Nature magazine shows that in
mice with a mutation that causes Duchenne muscular dystrophy, the drug starts
dystrophin production and restores their muscles to health. The research
also suggests it should also work against more than 1,800 other genetic illnesses.
The drug is able to repair faulty genes in the body that lead to crippling
illness, and is already in the early stages of human trials after promising
results in mice. Scientists say that if the trials go well, it could be licensed
as early as 2009. The pill works by effectively forcing the body to ignore
genetic mutations, and to produce normal proteins, rather than the mutated
versions which lead to disease. Patients would have to take it throughout
their lives.
Source: The primary sources cited above,
BBC News, New York Times (NYT), Washington
Post (WP), Mercury News, Bayarea.com,
Chicago Tribune, USA Today, Intellihealthnews,
Deccan Chronicle (DC), the Hindu,
Hindustan Times, Times of India, AP,
Reuters, AFP, womenfitness.net, Biospace
etc.
Notice: The content of the articles is intended to
provide general information. Specialist advice should be sought about
your specific circumstances.
|
|
|
|